![]() |
市場調査レポート
商品コード
1342081
創薬向けAIの世界市場の予測(~2030年)Artificial Intelligence in Drug Discovery Market Research Report Forecast to 2030 |
||||||
|
創薬向けAIの世界市場の予測(~2030年) |
出版日: 2023年09月01日
発行: Market Research Future
ページ情報: 英文 132 Pages
納期: 即納可能
![]() |
世界の創薬向けAIの市場規模は、予測期間中にCAGRで29.83%の大幅な成長が予測されています。創薬向けAIの受け入れの増加や、創薬向けAIに対する主な取り組みの高まり、AIを活用する新しい創薬企業の増加が、事業部門の発展を促進しています。
地域の考察
北米市場が2022年にもっとも大きなシェアを占めました。
欧州市場が2番目に大きなシェアを占めています。
アジア太平洋市場が2023年~2030年に大きな伸びを示す見込みです。
中東・アフリカ・ラテンアメリカ市場は、慢性疾患や感染性疾患の流行による医薬品需要の増加により、発展する可能性が高いです。
当レポートでは、世界の創薬向けAI市場について調査分析し、市場力学、地域とセグメントの分析、企業プロファイルなどを提供しています。
The Artificial Intelligence in Drug Discovery Market is anticipated to register a substantial CAGR of 29.83% during the forecast period. The increasing reception of simulated intelligence in drug discovery, rising key initiatives for man-made intelligence in drug discovery, and the increasing number of man-made intelligence-powered drug discovery new companies are driving business sector development.
The reception of simulated intelligence in drug discovery is rising among industries, including drug and biotechnology organizations. This is essentially owing to the way that artificial intelligence offers progressed benefits to discovering drug particles and paces up the drug discovery process. Further, artificial intelligence gives significant insights to work on the designing, optimizing, and synthesizing of drugs. There are a few factors that are increasing the reception of man-made intelligence for drug discovery. The absolute most predominant ones include the rising incidences of ongoing illnesses and accuracy medicine, owing to the emerging way to deal with the counteraction and treatment of sicknesses. Besides, a few market members are increasing the accuracy of their drug portfolios, a cycle that has been seen to exhibit an increase in the reception of man-made intelligence advancements.
Based on product and service Artificial Intelligence in Drug Discovery, is classified into software and services. Based on a molecule type the market is divided into large molecules and small molecules. The Market of Artificial Intelligence in Drug Discovery based on technology is divided into machine learning, deep learning, and others.
Based on an indication the market is classified into immuno-oncology, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and others. Based on an application the market is categorized into target identification, candidate screening, de novo drug designing, drug optimization and repurposing, and preclinical testing.
Regional Insights
The North American artificial intelligence in the drug discovery market represented the biggest piece of the pie in 2022. This is because of the increasing incidences of ongoing illnesses, many leading new companies, and increasing drug Research and development investments in the region.
Europe's artificial intelligence in the drug discovery market represents the second-biggest piece of the pie because of the rising pervasiveness of uncommon illnesses across Europe and increasing the demand for a simulated intelligence-driven stage for drug discovery. Moreover, Germany's market of artificial intelligence
The Asia-Pacific artificial intelligence in drug discovery market is supposed to develop at a huge offer from 2023 to 2030. This is because of the rising weight of sickness and the tremendous number of biopharmaceutical industries that are adopting computer-based intelligence abilities in the Asia-Pacific region.
The rest of the World is fragmented into the Center East, Africa, and Latin America. Artificial intelligence in the drug discovery market in the previously mentioned regions is probably going to observe development because of the increasing demand for drugs because of the rising incidences of persistent and infectious illnesses.
Key Companies in the Artificial Intelligence in Drug Discovery Market include IBM (US), Alphabet Inc (US), Atomwise Inc (US), Deep Genomics (Canada), Cloud Pharmaceuticals, Inc (US), Microsoft corporation (US), Insilico Medicine (China), Cyclica (Canada), BenevolentAI (UK), and Exscientia (UK).
TABLE OF CONTENTS